Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/11/2024 | $24.00 | Buy | Craig Hallum |
| 9/8/2022 | $17.00 | Buy | B. Riley Securities |
| 10/14/2021 | $16.00 | Buy | B. Riley Securities |
| 9/24/2021 | $15.00 | Buy | Aegis Capital |
| 7/2/2021 | $14.25 | Buy | Ladenburg Thalmann |
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, it has entered into an agreement with Apexus to make IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3% and other Harrow products available through its 340B Prime Vendor Program.
As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here's the latest list of major overbought players in this sector. Harrow Inc (NASDAQ:HROW) On June 21, Craig-Hallum analyst Chase Knickerbocker maintained Har
Craig-Hallum analyst Chase Knickerbocker maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target from $26 to $30.
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 14, 2024 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the third quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market close. The Company will also post its third quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Thursday, November 14, 2024, to discuss the results and provide a business update. Conference Call Information Participants can access the live conferen
Second Quarter 2024 and Recent Selected Highlights: Record revenues of $48.9 million GAAP net loss of $(6.5) million Adjusted EBITDA of $8.8 million Cash and cash equivalents of $71.0 million as of June 30, 2024 IHEEZO® customer unit demand volume increased by 98% from the first quarter of 2024 IHEEZO supply agreements total 24 agreements to date in 2024, including a recent win with the largest and highest volume U.S. retina practice group VEVYE® total prescriptions increased by 212% from the first quarter of 2024 Anterior Segment revenues up over 40% from the first quarter of 2024 Record quarterly revenues from Harrow's ImprimisRx subsidiary Harrow (NASDAQ:HRO
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 8, 2024 Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2024, on Wednesday, August 7, 2024, after the market close. The Company will also post its second quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Thursday, August 8, 2024, to discuss the results and provide a business update. Conference Call Information Participants can access the live conference call via webcast
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced the nationwide launch of a new digital patient access solution in collaboration with Asembia, a leading provider of specialty pharmacy and patient support hub services. This multi-year exclusive partnership is designed to expand access to Harrow's ophthalmic branded products, including FLAREX®, ILEVRO®, MAXIDEX®, MAXITROL®, NATACYN®, NEVANAC®, TOBRADEX® ST, VERKAZIA®, VEVYE®, VIGAMOX®, and ZERVIATE®, by simplifying the prescribing process for eyecare professionals and improving both accessibility and affordability for patients. ASPN Pharmacies is Asembia's non-dispensing pharmacy, specializing in
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 14, 2024 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the third quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market close. The Company will also post its third quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Thursday, November 14, 2024, to discuss the results and provide a business update. Conference Call Information Participants can access the live conferen
Topline Readout Expected in Q4 2024 FDA Agrees to a MELT-300 Phase 3 Special Protocol Assessment Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced the dosing of the last patient in its pivotal Phase 3 study evaluating the safety and efficacy of its lead product candidate, MELT‑300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. MELT-300 combines fixed doses of midazolam (3mg) and ketamine (50mg) in one tablet that is administered sublingually using Catalent's proprietary Zydis® delivery technology to dissolve and absorb the active ingredients across the sublingual
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
Craig Hallum initiated coverage of Harrow with a rating of Buy and set a new price target of $24.00
B. Riley Securities resumed coverage of Harrow Health with a rating of Buy and set a new price target of $17.00
B. Riley Securities resumed coverage of Harrow Health with a rating of Buy and set a new price target of $16.00
Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saharek, Harrow's Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow's commercial business, focusing on the day-to-day management of Harrow's market‑leading compounded division. DiPasquale
Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance, responsible for overseeing and managing all regulatory related submissions and strategy related to the Company's portfolio of new and existing products. Dr. Mannebach's successful 30-year career in the pharmaceutical industry, much of which was focused in ophthalmology, includes leadership roles in regulatory affairs, quality assurance, program management and pharmaceutical product development. "Dr. Mannebach brings to Harrow decades of regulatory and clinical expertise and leadership –specifically in ophth
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13G - HARROW, INC. (0001360214) (Subject)
8-K - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
10-Q - HARROW, INC. (0001360214) (Filer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)